<DOC>
	<DOC>NCT02314689</DOC>
	<brief_summary>The purpose of this study is to assess the maximum tolerated dose, safety and pharmacokinetics of an investigational drug, intravenous (IV) citrulline, in subjects in steady-state sickle cell disease.</brief_summary>
	<brief_title>A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>Sickle cell disease genotypes (HbSS, HbS/β° thalassemia, HbS/β+thalassemia, HbSC) Presence of any acute illness defined by fever &gt;100.4° F within the past 48 hours Presence of sickle cell pain crisis defined by the presence of pain requiring oral or parental opioid therapy. Presence of acute chest syndrome or presence of any other complication related to sickle cell disease requiring hospitalization such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, and patients with diabetes etc. Severe anemia (hemoglobin &lt; 5g/dL) History of red blood cell transfusion within the last 14 days Systemic steroid therapy within the last 48 hours Pregnant (as confirmed by a negative urine pregnancy test) or lactating female Alanine/aspartate transferase &gt;2x upper limit of normal laboratory range for age. Elevated serum creatinine &gt;1.5mg/dL Patients with an inability to give consent will be excluded Medications that are known to be contraindicated with use of Lcitrulline (concurrent use of hydroxyurea will be allowed). History of diabetes due to risk of electrolyte imbalance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>